XML 24 R14.htm IDEA: XBRL DOCUMENT v3.25.3
Expenses
 12 Months Ended
Jun. 30, 2025
Disclosure [Abstract]  
Expenses
Note 7. Expenses
Loss before income tax includes the following specific expenses:

 
  
2025
A$’000
 
  
2024
A$’000
 
  
2023
A$’000
 
Research and development expense
         
EVT-801
program costs
      1,391        5,277        5,060  
Cantrixil program costs
      2        1        5  
Paxalisib program costs
      3,031        7,551        5,618  
Scientific Advisory Board costs
      —         —         31  
Employee benefits expense
- salaries & wages and staff benefits
      1,761        2,161        2,250  
- superannuation
      34        36        29  
- share based payments
      172        485        702  
  
 
 
     
 
 
     
 
 
  
Total research & development expense (excluding amortisation)
      6,391        15,511        13,695  
Amortisation
         
Paxalisib licensing agreement
      542        1,084        1,084  
Evotech licensing agreement
      392        785        785  
  
 
 
     
 
 
     
 
 
  
Total amortisation
      934        1,869        1,869  
  
 
 
     
 
 
     
 
 
  
Total research & development expense
      7,325        17,380        15,564  
Net foreign exchange loss
         
Net foreign exchange loss/(gain)
      310        (20 )       46  
Lease
         
Expense relating to short term lease
      59        124        152  
Superannuation expense
         
Defined contribution superannuation expense
      54        88        131  
Employee benefits expense G&A
         
- salaries & wages and staff benefits
      1,062        486        1,467  
- superannuation
      20        52        102  
- share based payments
      481        48        457  
  
 
 
     
 
 
     
 
 
  
Total employee benefits expense G&A
      1,563        586        2,026